Praxis Precision Medicines, Inc. 8-K

What Happened
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K on April 14, 2026, announcing that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor in adults. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027, and indicated it is not planning to hold an advisory committee meeting.

Key Details

• Filing: Form 8-K filed April 14, 2026 (Item 8.01, Other Events).
• Drug: Ulixacaltamide HCl for treatment of essential tremor in adults.
• Regulatory timeline: FDA acceptance for review with PDUFA target action date of January 29, 2027.
• Advisory committee: FDA does not plan to hold an advisory committee meeting for this NDA review.

Why It Matters
FDA acceptance of an NDA is a major regulatory milestone that formally starts the agency’s review of a drug candidate. The PDUFA date gives investors a clear timeline for when the FDA aims to make a decision, and the lack of a planned advisory committee meeting can indicate a more streamlined review process. This update is material for investors tracking Praxis’s development progress and potential path toward commercialization for ulixacaltamide.